世界の表皮成長因子受容体阻害剤市場の規模、シェア、トレンド分析レポート – 業界の概要と 2032 年までの予測

上皮成長因子受容体阻害剤市場分析

上皮成長因子受容体阻害剤市場は、がん、特に非小細胞肺がん（NSCLC）の罹患率の増加と、標的療法の需要の高まりによって推進されています。エルロチニブ、ゲフィチニブ、オシメルチニブなどのこれらの阻害剤は、がん細胞の増殖に関与するタンパク質であるEGFRの活動を阻害する上で重要な役割を果たします。これらの阻害剤は、EGFR変異がん患者の生存率を改善する有望な結果を示しています。最近の開発は、耐性を克服し、有効性を向上させるように設計された次世代阻害剤に焦点を当てています。進行中の臨床試験では、併用療法を含むそれらの使用が拡大しています。個別化医療が進歩するにつれて、これらの治療法の需要が高まると予想されます。さらに、診断とバイオマーカーの改善により患者の選択が強化され、市場の成長を促進しています。

上皮成長因子受容体阻害剤市場規模

世界の表皮成長因子受容体阻害剤市場規模は、2024年に141億米ドルと評価され、2025年から2032年の予測期間中に9.00%のCAGRで成長し、2032年には281億米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

上皮成長因子受容体阻害剤の市場動向

「免疫療法と化学療法における治療」

上皮成長因子受容体阻害剤市場は、標的がん治療の進歩に牽引されて大幅な成長を遂げています。主に非小細胞肺がんやその他の固形腫瘍の治療に使用されるこれらの阻害剤は、EGFRを阻害してがん細胞の増殖を防ぎます。次世代のEGFR阻害剤の革新は、既存の治療に対する耐性を克服し、有効性と患者の転帰を向上させることを目指しています。注目すべき傾向の1つは、併用療法への移行です。EGFR阻害剤は、免疫療法や化学療法などの他の治療と併用され、反応率を改善し、再発を減らします。高度な診断とバイオマーカー検査の助けを借りた個別化医療への注目の高まりも、市場拡大の原動力となっています。新しい治療法が登場するにつれて、市場は精密治療にさらに重点を置きながら進化し続けると予想されます。

レポートの範囲と上皮成長因子受容体阻害剤市場のセグメンテーション

上皮成長因子受容体阻害剤市場の定義

上皮成長因子受容体阻害剤は、癌細胞の増殖と拡散に関与するタンパク質である上皮成長因子受容体の作用を阻害する標的癌治療薬の一種です。EGFR は、非小細胞肺癌、大腸癌、頭頸部癌など、さまざまな癌で過剰発現または変異することがよくあります。これらの薬剤は EGFR を阻害することで、癌細胞の増殖を防ぎ、腫瘍の成長を抑え、患者の転帰を改善できます。

上皮成長因子受容体阻害剤市場の動向

ドライバー

• がんの発症率の上昇

がん、特に非小細胞肺がん（NSCLC）と大腸がんの罹患率の上昇により、上皮成長因子受容体（EGFR）阻害剤などの効果的な治療オプションの需要が大幅に高まっています。世界のがんの負担が増加し続ける中、EGFR阻害剤は、EGFRの変異または過剰発現に関連するがんの治療における重要な要素として浮上しています。これらの標的療法は、がん細胞を標的にしながら健康な組織へのダメージを最小限に抑えることで、従来の化学療法に比べてより効果的な治療を提供します。精密腫瘍学のニーズが高まるにつれて、EGFR阻害剤の需要は拡大し続け、市場の成長を促進しています。

• 次世代EGFR阻害剤

次世代の上皮成長因子受容体 (EGFR) 阻害剤の開発は、市場成長の重要な原動力です。これらの新しい治療法は、以前の EGFR 阻害剤に対する耐性を克服するように設計されているからです。第一世代の治療に最初は反応した患者の多くは、最終的に耐性を発症し、治療の長期的な有効性が制限されます。オシメルチニブなどの次世代阻害剤は、EGFR 遺伝子の特定の変異を標的とし、有効性の向上と長期的な疾患制御の可能性を提供します。この進歩は、特に非小細胞肺がんにおけるがん治療の重要な満たされていないニーズに対処するのに役立ち、臨床診療における EGFR 阻害剤の採用の増加を促進しています。

機会

• 遺伝子検査とバイオマーカーの進歩

Advances in genetic testing and biomarker identification are creating significant opportunities in the epidermal growth factor receptor (EGFR) inhibitors market. These innovations allow for more personalized treatments by accurately identifying patients with EGFR mutations or overexpression, ensuring that only those most likely to benefit from EGFR inhibitors receive them. This precise patient selection improves treatment efficacy and reduces unnecessary side effects, contributing to better clinical outcomes. As genetic testing becomes more widespread and accessible, the demand for EGFR inhibitors tailored to individual genetic profiles is expected to grow, creating substantial growth opportunities within the market.

• Rapid Growth of Diagnostic Technologies

The growth of diagnostic technologies that identify EGFR mutations is a key opportunity for the epidermal growth factor receptor (EGFR) inhibitors market. Advanced diagnostic tools, such as next-generation sequencing and liquid biopsy, enable clinicians to accurately identify patients with EGFR mutations, ensuring more precise and effective treatment selection. This precision medicine approach not only improves patient outcomes but also increases the demand for EGFR-targeted therapies, as patients can now be treated based on their genetic profiles. As diagnostic technologies continue to evolve, they will play a crucial role in expanding the use of EGFR inhibitors, driving market growth and improving overall treatment success.

Restraints/Challenges

• Regulatory and Market Access Barriers

Regulatory hurdles and the requirement for extensive clinical trials to gain approval in various regions present a significant challenge for the epidermal growth factor receptor (EGFR) inhibitors market. Developing and launching new EGFR inhibitors often involves lengthy and costly clinical trial processes to demonstrate safety and efficacy across diverse patient populations. Additionally, regulatory agencies in different regions have varying approval timelines and requirements, which can delay the introduction of innovative treatments to the market. These delays limit patient access to potentially life-saving therapies and hinder the overall growth and expansion of the EGFR inhibitors market.

•  High Cost of Treatment

The high cost of epidermal growth factor receptor (EGFR) inhibitors, particularly next-generation therapies, is a significant market restraint. These treatments, while highly effective, can be prohibitively expensive, which limits their accessibility, especially in low-income regions or among underinsured populations. The financial burden associated with long-term therapy may lead to lower adoption rates and create disparities in patient access to cutting-edge cancer treatments. As a result, despite the clinical benefits, the widespread use of EGFR inhibitors is hindered in regions where healthcare resources are limited, ultimately slowing the overall growth of the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Epidermal Growth Factor Receptor Inhibitors Market Scope

The market is segmented on the basis of application, drugs, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

• Lung Cancer
• Liver Cancer
• Breast Cancer
• Others

Drugs

• Cetuximab
• Erlotinib
• Gefitinib
• Others

Route of Administration

• Oral
• Injectable
• Others

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Epidermal Growth Factor Receptor Inhibitors Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, application, drugs, route of administration, end users, and distribution channel referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the epidermal growth factor receptor inhibitors market, driven by the widespread availability of advanced treatments and a robust healthcare infrastructure. The region benefits from cutting-edge medical research and development, ensuring timely access to the latest therapies. Additionally, the high healthcare expenditure in North America supports the adoption of these targeted therapies, further fueling market growth.

The Asia-Pacific region is anticipated to experience significant growth in the epidermal growth factor receptor inhibitors market between 2025 and 2032. This growth is driven by various patient assistance programs initiated by both pharmaceutical vendors and governments across the region. These initiatives aim to improve access to treatment, contributing to increased adoption of EGFR inhibitors and driving market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Epidermal Growth Factor Receptor Inhibitors Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Epidermal Growth Factor Receptor Inhibitors Market Leaders Operating in the Market Are:

• AstraZeneca (U.K.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc. (U.S.)
• Spectrum Pharmaceuticals (U.S.)
• CULLINAN THERAPEUTICS, INC. (U.S.)
• TAIHO PHARMACEUTICAL CO., LTD. (Japan)
• Lutris Pharma (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Puma Biotechnology, Inc. (U.S.)
• Apollomics, Inc. (U.S.)
• HUTCHMED (China)
• Genentech, Inc. (U.S.)
• ASLAN Pharmaceuticals (Singapore)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Sihuan Pharmaceutical Holdings Group Ltd (China)
• Astellas Pharma Inc. (Japan)
• Celldex Therapeutics (U.S.)
• Yuhan (South Korea)
• Johnson & Johnson Services, Inc. (U.S.)

Latest Developments in Epidermal Growth Factor Receptor Inhibitors Market

• In January 2022, Betta Pharmaceuticals received regulatory approval for Icotinib for the treatment of non-small cell lung cancer (NSCLC) in China. This approval marks a significant milestone in expanding treatment options for NSCLC patients in the region. Icotinib, an EGFR inhibitor, is expected to enhance the availability of targeted therapies for patients with EGFR-mutated lung cancer in China
• 2022年6月、武田オンコロジーはポーランドで非小細胞肺がん（NSCLC）の治療薬としてブリガチニブを導入しました。この導入により、特にEGFR変異を持つNSCLC患者に対する新しい標的療法へのアクセスが拡大します。ブリガチニブは有望な治療オプションを提供し、ポーランドの肺がん患者が利用できる治療法を強化します。
• 2022年12月、江蘇漢創薬は、欧州連合で非小細胞肺がん（NSCLC）の治療薬としてオーモレルチニブの事前登録申請を提出した。これは、EUでオーモレルチニブをNSCLC患者に提供するための重要な一歩となる。この薬はEGFR阻害剤であり、この地域のEGFR変異を持つ患者に標的治療の選択肢を提供することを目指している。

SKU-50344